Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zylox-Tonbridge Medical Technology Co EBITDA Margin % Related Terms
Zylox-Tonbridge Medical Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co EBITDA Margin % Chart
HKSE:02190 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) has a EBITDA Margin % of 20.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. According to the industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #166 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 20.4%.
Is Zylox-Tonbridge Medical Technology Co's EBITDA Margin % too high?
Zylox-Tonbridge Medical Technology Co's current EBITDA Margin % is 20.09%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.63. Zylox-Tonbridge Medical Technology Co's value of 20.09% is 163.5% above this industry median. Based on the distribution chart, Zylox-Tonbridge Medical Technology Co ranks #166 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #166 out of 814 companies for EBITDA Margin %. This places Zylox-Tonbridge Medical Technology Co in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.63. Zylox-Tonbridge Medical Technology Co's value of 20.09% is 163.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.63, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zylox-Tonbridge Medical Technology Co's current EBITDA Margin % of 20.09% is 163.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zylox-Tonbridge Medical Technology Co's current EBITDA Margin % is 20.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (HKSE:02190) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$35.80, compared to a current price of HK$19.95 — trading 44.3% below its estimated fair value. The current EBITDA Margin % is 20.09% and 163.5% above the Medical Devices & Instruments industry median of 7.63. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (HKSE:02190), the current EBITDA Margin % is 20.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (HKSE:02190) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of HK$19.95 is trading 44.3% below its estimated GF Value™ of HK$35.80.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02190:
EBITDA Margin %: 20.09%
GF Value™: HK$35.80 vs. price of HK$19.95 (44.3% below fair value)
Industry Position: 163.5% above the Medical Devices & Instruments median (#166 of 814)
No single metric tells the full story. See the HKSE:02190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
82GF Score
Get the complete analysis for HKSE:02190
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02190 has been successfully added to your 
